These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26849823)

  • 41. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
    Levitt NS; Ratanjee BD; Abrahamson MJ
    Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of disease duration on coronary calcification in patients with acromegaly.
    Herrmann BL; Severing M; Schmermund A; Berg C; Budde T; Erbel R; Mann K
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):417-22. PubMed ID: 19373755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population.
    Granada ML; Ulied A; Casanueva FF; Pico A; Lucas T; Torres E; Sanmartí A
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):942-50. PubMed ID: 17980002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosis of acromegaly: state of the art.
    Kannan S; Kennedy L
    Expert Opin Med Diagn; 2013 Sep; 7(5):443-53. PubMed ID: 23971897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels.
    Schneider HJ; Sievers C; Saller B; Wittchen HU; Stalla GK
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):432-5. PubMed ID: 18284644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
    Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
    Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
    Attanasio R; Baldelli R; Pivonello R; Grottoli S; Bocca L; Gasco V; Giusti M; Tamburrano G; Colao A; Cozzi R
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bilateral carpal tunnel syndrome revealing an acromegaly: a case report.
    Toulali F; Srifi H; Talbi D; Guerboub AA
    Pan Afr Med J; 2023; 44():186. PubMed ID: 37484588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient-reported outcome after carpal tunnel release for advanced disease: a prospective and longitudinal assessment in patients older than age 70.
    Leit ME; Weiser RW; Tomaino MM
    J Hand Surg Am; 2004 May; 29(3):379-83. PubMed ID: 15140475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
    Fukuoka H; Takahashi Y; Iida K; Kudo T; Nishizawa H; Imanaka M; Takeno R; Iguchi G; Takahashi K; Okimura Y; Kaji H; Chihara K
    Horm Res; 2008; 69(3):165-71. PubMed ID: 18219220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prevalence of silent acromegaly in prolactinomas is very low.
    Bona C; Prencipe N; Jaffrain-Rea ML; Carosi G; Lanzi R; Ambrosio MR; Pasquali D; Vettor R; Cannavò S; Ghigo E; Grottoli S
    J Endocrinol Invest; 2021 Mar; 44(3):531-539. PubMed ID: 32594452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed.
    Reid TJ; Post KD; Bruce JN; Nabi Kanibir M; Reyes-Vidal CM; Freda PU
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):203-8. PubMed ID: 19473180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral nervous system assessment in acromegaly patients under somatostatin analogue therapy.
    Alibas H; Gogas Yavuz D; Kahraman Koytak P; Uygur M; Tanridag T; Uluc K
    J Endocrinol Invest; 2017 Jan; 40(1):33-40. PubMed ID: 27484912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.